ERBC (ex CERB) has acquired RTC
The European Research Biology Center (ERBC) has acquired the Research Toxicology Center (RTC).
ERBC provides healthcare and chemical professionals a comprehensive range of experimental capabilities and services, from preclinical proof-of-concept to market of any type of drug candidate or chemical compound. Each project is managed by a study director, relying on a multi-disciplinary team of experts, notably in general pharmacology, cardiology, electrophysiology and pathophysiology, and also benefiting from a world-class academic and private network.
RTC is a fully fledged contract research laboratory located near Rome, Italy, with a track record spanning more than four decades. RTC collaborates with a large range of industrial clients including the pharmaceutical, biotech, chemical, agro-chemical and biocide industries.
Oaklins' team in France advised the buyer in this transaction.
![](/api/deal-hero-image/105812/deal-hero-image.jpg)
![](/api/deal-party-images/105812/deal-parties.png)
![](/api/deal-client-photo/105812/deal-client-photo.jpg)
Serge Richard
CEO, ERBC
Talk to the deal team
Related deals
Bellefleur has been acquired by Domidep
Belgian nursing home Bellefleur has been sold to Domidep, one of France’s largest private nursing home operators.
Learn moreTransDigm Group has acquired Raptor Scientific from L Squared Capital Partners for US$655 million
TransDigm Group Incorporated (NYSE: TDG) has successfully completed its acquisition of Raptor Scientific, a portfolio company of L Squared Capital Partners, for approximately US$655 million in cash.
Learn moreRoyal Reesink has sold Motrac Industries to Anders Invest
Royal Reesink and Anders Invest have completed the sale of Motrac Industries, a specialist in hydraulic and electrical engineering.
Learn more